Michael Huang
Directeur/Membre du Conseil chez Viracta Subsidiary, Inc.
Profil
Michael L.
Huang was the founder of Neurovive Pharmaceutical Asia, Inc. founded in 2014, where he held the title of Chief Executive Officer from 2014 to 2017.
Currently, he holds the position of Director at Windgap Medical, Inc. and Viracta Subsidiary, Inc. since 2021 and 2019 respectively.
He is also a Director at Regenacy Pharmaceuticals LLC, Point Robotics Medtech, Inc., Elixiron Immunotherapeutics, Inc., and Digestive Health Specialists PC.
In the past, he worked as a Director at Sunesis Pharmaceuticals, Inc., Fractyl Health, Inc., and Frequency Therapeutics, Inc. He was also an Independent Director at Viracta Therapeutics, Inc. from 2019 to 2022.
Additionally, he worked as Head-Investor Relations at TWi Pharmaceuticals, Inc. Mr. Huang completed his undergraduate studies at The University of Texas at Austin, his graduate studies at The University of Texas at Arlington, and his MBA at Jones Graduate School of Business.
Postes actifs de Michael Huang
| Sociétés | Poste | Début |
|---|---|---|
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Directeur/Membre du Conseil | 01/01/2019 |
Regenacy Pharmaceuticals LLC
 Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA. | Directeur/Membre du Conseil | - |
Point Robotics Medtech, Inc.
 Point Robotics Medtech, Inc. Wholesale DistributorsDistribution Services Point Robotics Medtech, Inc. is a private company based in Taiwan that specializes in minimally invasive surgical technologies. In May 2020, the Taiwanese company completed its series-A fundraising from government funds, Taiwania Capital, and Translink Capital. Point Robotics Medtech will continue to focus on the development and regulatory approvals of next-generation products to maintain its leading position in the high-end surgical robotics market. Founded in 2016, the company has two major product lines\: the "Kinguide Robotic-Assisted Surgical System" and the "Kinguide Agile Hybrid Navigation System." | Directeur/Membre du Conseil | - |
Windgap Medical, Inc.
 Windgap Medical, Inc. Pharmaceuticals: MajorHealth Technology Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA. | Directeur/Membre du Conseil | 01/01/2021 |
Anciens postes connus de Michael Huang
| Sociétés | Poste | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 23/08/2022 |
| Neurovive Pharmaceutical Asia, Inc. | Directeur Général | 01/01/2017 |
| TWI PHARMACEUTICALS INC | Investor Relations Contact | - |
| VIRACTA THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
| FRACTYL HEALTH, INC. | Directeur/Membre du Conseil | - |
Formation de Michael Huang
| The University of Texas at Austin | Undergraduate Degree |
| The University of Texas at Arlington | Graduate Degree |
| Jones Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| FRACTYL HEALTH, INC. | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Windgap Medical, Inc.
Windgap Medical, Inc. Pharmaceuticals: MajorHealth Technology Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA. | Health Technology |
TWi Pharmaceuticals, Inc.
 TWi Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals, Inc. operates as a technology-based special pharmaceutical company. The firm engages in the development and commercialization of high barrier generics drugs. Its products include donepezil hydrochloride tablets, megestrol acetate oral suspension, hydroquinone cream, guanfacine extended-release tablets and nifedipine extended-release tablets. The company was founded by Chih Ming Chen on December 1, 1997 and is headquartered in Taipei, Taiwan. | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
Frequency Therapeutics, Inc.
 Frequency Therapeutics, Inc. BiotechnologyHealth Technology Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA. | Health Technology |
Regenacy Pharmaceuticals LLC
Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA. | Health Technology |
Point Robotics Medtech, Inc.
Point Robotics Medtech, Inc. Wholesale DistributorsDistribution Services Point Robotics Medtech, Inc. is a private company based in Taiwan that specializes in minimally invasive surgical technologies. In May 2020, the Taiwanese company completed its series-A fundraising from government funds, Taiwania Capital, and Translink Capital. Point Robotics Medtech will continue to focus on the development and regulatory approvals of next-generation products to maintain its leading position in the high-end surgical robotics market. Founded in 2016, the company has two major product lines\: the "Kinguide Robotic-Assisted Surgical System" and the "Kinguide Agile Hybrid Navigation System." | Distribution Services |
| Neurovive Pharmaceutical Asia, Inc. |
